RxDoctor Payments Data

Ronda Lehn

Nurse Practitioner · Cincinnati, OHNPI 1679749568

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,461in general payments, 2019–2025

Across 207 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$640
  • Novo Nordisk$400
  • Astellas Pharma US Inc$278
  • AstraZeneca$271
  • Lilly USA, LLC$213
  • GSK$139
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,461 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio →

Medicare billing

Part B allowed, 2024
$18,708
Medicare patients
110
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,775
SymbicortBudesonide/Formoterol Fumarate11$2,483
Doxycycline Monohydrate78$1,346
Albuterol Sulfate HfaAlbuterol Sulfate20$492
Omeprazole27$486
Estradiol11$409
Gabapentin45$353
Famotidine30$326
Potassium Chloride11$278
Carvedilol14$255
Duloxetine Hcl21$252
Nystatin16$237
Atorvastatin Calcium39$227
Levothyroxine Sodium39$194
Pantoprazole Sodium53$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$139$19,77528 claims
AstraZenecaSymbicort$271$2,48311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Cincinnati

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →